U.S. Antibody Drug Conjugates Market (2025 - 2030) Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer), By Technology, By Product, By Target, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Market Definition
                    1.3. Information Procurement
                        1.3.1. Purchased Database
                        1.3.2. GVR’s Internal Database
                        1.3.3. Secondary Sources & Third-Party Perspectives
                        1.3.4. Primary Research
                    1.4. Information Analysis
                        1.4.1. Data Analysis Models
                    1.5. Market Formulation & Data Visualization
                    1.6. Data Validation & Publishing
Chapter 2. Executive Summary
                    2.1. Market Snapshot
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Antibody Drug Conjugates Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Related Market Outlook
                    3.2. Industry Value Chain Analysis
                    3.3. Regulatory Framework
                    3.4. Market Dynamics
                        3.4.1. Market Driver Analysis
                        3.4.2. Market Restraint Analysis
                        3.4.3. Industry Challenges
                        3.4.4. Industry Opportunities
                    3.5. Industry Analysis Tools
                        3.5.1. Porter’s Five Forces Analysis
                        3.5.2. Macro-environmental Analysis
Chapter 4. U.S. Antibody Drug Conjugates Market: Application Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Antibody Drug Conjugates Market: Application Movement Analysis & Market Share, 2024 & 2030
                    4.3. Blood Cancer
                        4.3.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        4.3.2. Leukemia
                            4.3.2.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        4.3.3. Lymphoma
                            4.3.3.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        4.3.4. Multiple Myeloma
                            4.3.4.1. Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    4.4. Breast Cancer
                        4.4.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    4.5. Urothelial Cancer & Bladder Cancer
                        4.5.1. Urothelial Cancer & Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    4.6. Other Cancer
                        4.6.1. Urothelial Cancer & Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Antibody Drug Conjugates Market: Product Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. Antibody Drug Conjugates Market: Product Movement Analysis & Market Share, 2024 & 2030
                    5.3. Kadcyla
                        5.3.1. Kadcyla Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    5.4. Enhertu
                        5.4.1. Enhertu Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    5.5. Adcetris
                        5.5.1. Adcetris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    5.6. Padcev
                        5.6.1. Padcev Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    5.7. Trodelvy
                        5.7.1. Trodelvy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    5.8. Polivy
                        5.8.1. Polivy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    5.9. Others
                        5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Antibody Drug Conjugates Market: Target Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. Antibody Drug Conjugates Market: Target Movement Analysis & Market Share, 2024 & 2030
                    6.3. HER2
                        6.3.1. HER2 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    6.4. CD22
                        6.4.1. CD22 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    6.5. CD30
                        6.5.1. CD30 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    6.6. Others
                        6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. U.S. Antibody Drug Conjugates Market: Technology Estimates & Trend Analysis
                    7.1. Segment Dashboard
                    7.2. U.S. Antibody Drug Conjugates Market: Technology Movement Analysis & Market Share, 2024 & 2030
                    7.3. Type
                        7.3.1. Type Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.3.2. Cleavable Linker
                            7.3.2.1. Cleavable Linker Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.3.3. Non-cleavable Linker
                            7.3.3.1. Non-cleavable Linker Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.3.4. Linkerless
                            7.3.4.1. Linkerless Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    7.4. Linker Technology Type
                        7.4.1. Linker Technology Type Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.4.2. VC
                            7.4.2.1. VC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.4.3. Sulfo-SPDB
                            7.4.3.1. Sulfo-SPDB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.4.4. VA
                            7.4.4.1. VA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.4.5. Hydrazone
                            7.4.5.1. Hydrazone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.4.6. Others
                            7.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                    7.5. Payload Technology
                        7.5.1. Payload Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.5.2. MMAE
                            7.5.2.1. MMAE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.5.3. MMAF
                            7.5.3.1. MMAF Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.5.4. DM4
                            7.5.4.1. DM4 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.5.5. Camptothecin
                            7.5.5.1. Camptothecin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                        7.5.6. Others
                            7.5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. U.S. Antibody Drug Conjugates Market - Competitive Landscape
                    8.1. Recent Developments & Impact Analysis, By Key Market Participants
                    8.2. Company Categorization
                    8.3. Company Heat Map
                    8.4. Position Analysis, 2024
                    8.5. Strategy Mapping
                        8.5.1. Expansion
                        8.5.2. Mergers & Acquisition
                        8.5.3. Partnerships & Collaborations
                        8.5.4. New Product Launches
                        8.5.5. Research and Development
                    8.6. Company Profiles
                        8.6.1. Seagen, Inc.
                            8.6.1.1. Participant’s overview
                            8.6.1.2. Financial performance
                            8.6.1.3. Product benchmarking
                            8.6.1.4. Recent developments
                        8.6.2. Takeda Pharmaceutical Company Ltd.
                            8.6.2.1. Participant’s overview
                            8.6.2.2. Financial performance
                            8.6.2.3. Product benchmarking
                            8.6.2.4. Recent developments
                        8.6.3. AstraZeneca
                            8.6.3.1. Participant’s overview
                            8.6.3.2. Financial performance
                            8.6.3.3. Product benchmarking
                            8.6.3.4. Recent developments
                        8.6.4. F. Hoffmann-La Roche Ltd.
                            8.6.4.1. Participant’s overview
                            8.6.4.2. Financial performance
                            8.6.4.3. Product benchmarking
                            8.6.4.4. Recent developments
                        8.6.5. Pfizer, Inc.
                            8.6.5.1. Participant’s overview
                            8.6.5.2. Financial performance
                            8.6.5.3. Product benchmarking
                            8.6.5.4. Recent developments
                        8.6.6. Gilead Sciences, Inc.
                            8.6.6.1. Participant’s overview
                            8.6.6.2. Financial performance
                            8.6.6.3. Product benchmarking
                            8.6.6.4. Recent developments
                        8.6.7. Daiichi Sankyo Company Ltd.
                            8.6.7.1. Participant’s overview
                            8.6.7.2. Financial performance
                            8.6.7.3. Product benchmarking
                            8.6.7.4. Recent developments
                        8.6.8. GlaxoSmithKline Plc
                            8.6.8.1. Participant’s overview
                            8.6.8.2. Financial performance
                            8.6.8.3. Product benchmarking
                            8.6.8.4. Recent developments
                        8.6.9. Astellas Pharma, Inc.
                            8.6.9.1. Participant’s overview
                            8.6.9.2. Financial performance
                            8.6.9.3. Product benchmarking
                            8.6.9.4. Recent developments
                        8.6.10. ADC Therapeutics SA
                            8.6.10.1. Participant’s overview
                            8.6.10.2. Financial performance
                            8.6.10.3. Product benchmarking
                            8.6.10.4. Recent developments

List of Tables

Table 1 List of abbreviations
Table 2 U.S. antibody drug conjugates market 2018 - 2030 (USD Million)
Table 3 U.S. antibody drug conjugates market estimates and forecasts by application, 2018 - 2030 (USD Million)
Table 4 U.S. antibody drug conjugates market estimates and forecasts by product, 2018 - 2030 (USD Million)
Table 5 U.S. antibody drug conjugates market estimates and forecasts by target, 2018 - 2030 (USD Million)
Table 6 U.S. antibody drug conjugates market estimates and forecasts by technology, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market Research Process
Fig. 2 Data Triangulation Techniques
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 QFD Modeling for Market Share Assessment
Fig. 6 Information Procurement
Fig. 7 Market Formulation and Validation
Fig. 8 Data Validating & Publishing
Fig. 9 Market Segmentation & Scope
Fig. 10 U.S. Antibody Drug Conjugates Market Snapshot
Fig. 11 Segment Snapshot (1/2)
Fig. 12 Segment Snapshot (1/2)
Fig. 13 Competitive Landscape Snapshot
Fig. 14 Parent market outlook
Fig. 15 U.S. Antibody Drug Conjugates Market Value, 2024 (USD Million)
Fig. 16 U.S. Antibody Drug Conjugates Market - Value Chain Analysis
Fig. 17 U.S. Antibody Drug Conjugates Market - Market Dynamics
Fig. 18 U.S. Antibody Drug Conjugates Market - PORTER’s Analysis
Fig. 19 U.S. Antibody Drug Conjugates Market - PESTEL Analysis
Fig. 20 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Application: Key Takeaways
Fig. 21 U.S. Antibody Drug Conjugates Market Share, by Application, 2024 & 2030
Fig. 22 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Application: Key Takeaways
Fig. 23 Blood Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 24 Leukemia Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 25 Lymphoma Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 26 Multiple Myeloma Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 27 Breast Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 28 Urothelial Cancer & Bladder Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 29 Other Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 30 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Product: Key Takeaways
Fig. 31 U.S. Antibody Drug Conjugates Market Share, by Product, 2024 & 2030
Fig. 32 Kadcyla Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 33 Enhertu Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 34 Adcetris Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 35 Padcev Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 36 Trodelvy Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 37 Polivy Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 38 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 39 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Target: Key Takeaways
Fig. 40 U.S. Antibody Drug Conjugates Market Share, by Target, 2024 & 2030
Fig. 41 HER2 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 42 CD22 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 43 CD30 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 44 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 45 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Technology: Key Takeaways
Fig. 46 U.S. Antibody Drug Conjugates Market Share, by Technology, 2024 & 2030
Fig. 47 Type Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 48 Cleavable Linker Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 49 Non-cleavable Linker Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 50 Linkerless Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 51 Linker Technology Type Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 52 VC Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 53 Sulfo-SPDB Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 54 VA Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 55 Hydrazone Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 56 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 57 Payload Technology Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 58 MMAE Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 59 MMAF Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 60 DM4 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 61 Camptothecin Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 62 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key Company Categorization
Fig. 64 Company Market Positioning
Fig. 65 Strategy Mapping